This Polycystic Ovarian Syndrome Treatment market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The polycystic ovarian syndrome treatment market size has grown strongly in recent years. It will grow from $4.78 billion in 2024 to $5.03 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increased awareness, advances in medical technology, lifestyle changes, pharmaceutical innovations, government initiatives.
The polycystic ovarian syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $6.81 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to personalized medicine, telemedicine and remote monitoring, research and development, rising prevalence, supportive regulatory environment. Major trends in the forecast period include holistic approach, patient-centered care, digital health solutions, multidisciplinary care, patient education.
The global rise in genetic and hormonal disorders is a key factor driving the growth of the polycystic ovarian syndrome (PCOS) treatment market. PCOS, a common hormonal disorder affecting premenopausal women, is characterized by reproductive, endocrine, and metabolic abnormalities. The global prevalence of PCOS ranges from 2.2% to 26%, with regional variations. For instance, it is reported at 2% to 7.5% in China, 6.3% in Sri Lanka, 9.13% in South India, and 22.5% in Maharashtra. The increasing incidence of genetic and hormonal disorders worldwide is expected to contribute significantly to the growth of the PCOS treatment market.
The surge in lifestyle and dietary changes is anticipated to propel the growth of the polycystic ovarian syndrome treatment market. Lifestyle and dietary changes involve modifying daily routines and eating habits, which can significantly impact the management and treatment of PCOS. These changes are often employed as primary or complementary approaches to alleviate symptoms and enhance the overall well-being of individuals with PCOS. For example, a McKinsey & Company article from October 2022 highlights the importance of healthy eating, with at least 70% of survey respondents in various countries expressing a desire to be healthy. Healthy eating is a priority for around half of consumers across all age groups. Hence, the increase in lifestyle and dietary changes is fostering the growth of the polycystic ovarian syndrome treatment market.
Major companies in the polycystic ovarian syndrome (PCOS) treatment market are focusing on strategic partnerships to develop comprehensive diagnostic test kits aimed at improving early detection and enabling timely intervention. This approach enhances treatment outcomes and meets the increasing demand for accurate and accessible diagnostic tools. Diagnostic test kits are designed to identify diseases or conditions by analyzing bodily samples such as blood or urine. For example, in October 2022, Veera Health, an India-based wellness and fitness service provider, collaborated with Tata 1mg, an India-based healthcare company, to introduce a comprehensive test for diagnosing PCOS. The diagnostic test kit plays a crucial role in detecting the condition early, which allows for personalized and targeted treatment plans. By utilizing a comprehensive approach, these kits provide insights into hormonal levels, metabolic markers, and other relevant factors, ensuring individuals receive accurate diagnoses for effective PCOS management.
Major companies operating in the polycystic ovarian syndrome treatment market are introducing innovative programs like the PCOS Drug Program to enhance their market presence. The PCOS Drug Program is a treatment plan that combines lifestyle modifications and medications to manage PCOS symptoms. For example, in April 2023, Celmatix Inc., a US-based biotech company, launched the PCOS Drug Program with the primary goal of improving ovarian function by addressing the root cause of PCOS symptoms. The program's latest medication initiative focuses on developing the first-ever oral FSH receptor.
Major companies operating in the polycystic ovarian syndrome treatment market include Bristol-Myer Squibb Co, Bayer AG, Pfizer Inc., Merck KGaA, Sanofi SA, AstraZeneca PLC, Novartis AG, Teva Pharmaceutical Industries Limited, Abbott Laboratories, Addex Therapeutics Ltd., BIOCAD, Allergan plc., Johnson and Johnson, Ferring Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Organon & Co, Forendo Pharma Ltd., GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Mylan NV, Lupin Pharmaceuticals Inc., HRA Pharma SAS, CooperSurgical Inc., TherapeuticsMD Inc., Agile Therapeutics Inc., OvaScience Inc., Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited, Glenmark Pharmaceuticals Limited.
Polycystic ovarian syndrome (PCOS) is a condition characterized by hormonal imbalances in females, resulting in elevated levels of male hormones, which in turn can lead to irregular menstrual cycles and increased difficulty in achieving pregnancy.
The primary categories of drugs used in the treatment of polycystic ovarian syndrome include oral contraceptives, ornithine decarboxylase inhibitors, insulin-sensitizing agents, anti-depressants, diuretics, and aromatase inhibitors. Oral contraceptives are hormone-based medications taken orally to prevent pregnancy. They work by inhibiting ovulation and preventing sperm from reaching the cervix. Various surgical procedures, such as ovarian wedge resection and laparoscopic ovarian drilling, are performed in medical facilities, including hospitals, clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, and feminist health centers.
The polycystic ovarian syndrome treatment market research report is one of a series of new reports that provides polycystic ovarian syndrome treatment market statistics, including polycystic ovarian syndrome treatment industry global market size, regional shares, competitors with a polycystic ovarian syndrome treatment market share, detailed polycystic ovarian syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the polycystic ovarian syndrome treatment industry. This polycystic ovarian syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
North America was the largest region in the polycystic ovarian syndrome treatment market in 2024. Western Europe was the second largest region in the polycystic ovarian syndrome treatment market. The regions covered in the polycystic ovarian syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the polycystic ovarian syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The polycystic ovarian syndrome treatment market includes revenue earned by first line drugs for treating hirustism, first line drugs for ovulation, and insulin sensitizing drugs. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The polycystic ovarian syndrome treatment market size has grown strongly in recent years. It will grow from $4.78 billion in 2024 to $5.03 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increased awareness, advances in medical technology, lifestyle changes, pharmaceutical innovations, government initiatives.
The polycystic ovarian syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $6.81 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to personalized medicine, telemedicine and remote monitoring, research and development, rising prevalence, supportive regulatory environment. Major trends in the forecast period include holistic approach, patient-centered care, digital health solutions, multidisciplinary care, patient education.
The global rise in genetic and hormonal disorders is a key factor driving the growth of the polycystic ovarian syndrome (PCOS) treatment market. PCOS, a common hormonal disorder affecting premenopausal women, is characterized by reproductive, endocrine, and metabolic abnormalities. The global prevalence of PCOS ranges from 2.2% to 26%, with regional variations. For instance, it is reported at 2% to 7.5% in China, 6.3% in Sri Lanka, 9.13% in South India, and 22.5% in Maharashtra. The increasing incidence of genetic and hormonal disorders worldwide is expected to contribute significantly to the growth of the PCOS treatment market.
The surge in lifestyle and dietary changes is anticipated to propel the growth of the polycystic ovarian syndrome treatment market. Lifestyle and dietary changes involve modifying daily routines and eating habits, which can significantly impact the management and treatment of PCOS. These changes are often employed as primary or complementary approaches to alleviate symptoms and enhance the overall well-being of individuals with PCOS. For example, a McKinsey & Company article from October 2022 highlights the importance of healthy eating, with at least 70% of survey respondents in various countries expressing a desire to be healthy. Healthy eating is a priority for around half of consumers across all age groups. Hence, the increase in lifestyle and dietary changes is fostering the growth of the polycystic ovarian syndrome treatment market.
Major companies in the polycystic ovarian syndrome (PCOS) treatment market are focusing on strategic partnerships to develop comprehensive diagnostic test kits aimed at improving early detection and enabling timely intervention. This approach enhances treatment outcomes and meets the increasing demand for accurate and accessible diagnostic tools. Diagnostic test kits are designed to identify diseases or conditions by analyzing bodily samples such as blood or urine. For example, in October 2022, Veera Health, an India-based wellness and fitness service provider, collaborated with Tata 1mg, an India-based healthcare company, to introduce a comprehensive test for diagnosing PCOS. The diagnostic test kit plays a crucial role in detecting the condition early, which allows for personalized and targeted treatment plans. By utilizing a comprehensive approach, these kits provide insights into hormonal levels, metabolic markers, and other relevant factors, ensuring individuals receive accurate diagnoses for effective PCOS management.
Major companies operating in the polycystic ovarian syndrome treatment market are introducing innovative programs like the PCOS Drug Program to enhance their market presence. The PCOS Drug Program is a treatment plan that combines lifestyle modifications and medications to manage PCOS symptoms. For example, in April 2023, Celmatix Inc., a US-based biotech company, launched the PCOS Drug Program with the primary goal of improving ovarian function by addressing the root cause of PCOS symptoms. The program's latest medication initiative focuses on developing the first-ever oral FSH receptor.
Major companies operating in the polycystic ovarian syndrome treatment market include Bristol-Myer Squibb Co, Bayer AG, Pfizer Inc., Merck KGaA, Sanofi SA, AstraZeneca PLC, Novartis AG, Teva Pharmaceutical Industries Limited, Abbott Laboratories, Addex Therapeutics Ltd., BIOCAD, Allergan plc., Johnson and Johnson, Ferring Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Organon & Co, Forendo Pharma Ltd., GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Mylan NV, Lupin Pharmaceuticals Inc., HRA Pharma SAS, CooperSurgical Inc., TherapeuticsMD Inc., Agile Therapeutics Inc., OvaScience Inc., Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited, Glenmark Pharmaceuticals Limited.
Polycystic ovarian syndrome (PCOS) is a condition characterized by hormonal imbalances in females, resulting in elevated levels of male hormones, which in turn can lead to irregular menstrual cycles and increased difficulty in achieving pregnancy.
The primary categories of drugs used in the treatment of polycystic ovarian syndrome include oral contraceptives, ornithine decarboxylase inhibitors, insulin-sensitizing agents, anti-depressants, diuretics, and aromatase inhibitors. Oral contraceptives are hormone-based medications taken orally to prevent pregnancy. They work by inhibiting ovulation and preventing sperm from reaching the cervix. Various surgical procedures, such as ovarian wedge resection and laparoscopic ovarian drilling, are performed in medical facilities, including hospitals, clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, and feminist health centers.
The polycystic ovarian syndrome treatment market research report is one of a series of new reports that provides polycystic ovarian syndrome treatment market statistics, including polycystic ovarian syndrome treatment industry global market size, regional shares, competitors with a polycystic ovarian syndrome treatment market share, detailed polycystic ovarian syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the polycystic ovarian syndrome treatment industry. This polycystic ovarian syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
North America was the largest region in the polycystic ovarian syndrome treatment market in 2024. Western Europe was the second largest region in the polycystic ovarian syndrome treatment market. The regions covered in the polycystic ovarian syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the polycystic ovarian syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The polycystic ovarian syndrome treatment market includes revenue earned by first line drugs for treating hirustism, first line drugs for ovulation, and insulin sensitizing drugs. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Polycystic Ovarian Syndrome Treatment Market Characteristics3. Polycystic Ovarian Syndrome Treatment Market Trends and Strategies4. Polycystic Ovarian Syndrome Treatment Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Polycystic Ovarian Syndrome Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Polycystic Ovarian Syndrome Treatment Market34. Recent Developments in the Polycystic Ovarian Syndrome Treatment Market
5. Global Polycystic Ovarian Syndrome Treatment Growth Analysis and Strategic Analysis Framework
6. Polycystic Ovarian Syndrome Treatment Market Segmentation
7. Polycystic Ovarian Syndrome Treatment Market Regional and Country Analysis
8. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market
9. China Polycystic Ovarian Syndrome Treatment Market
10. India Polycystic Ovarian Syndrome Treatment Market
11. Japan Polycystic Ovarian Syndrome Treatment Market
12. Australia Polycystic Ovarian Syndrome Treatment Market
13. Indonesia Polycystic Ovarian Syndrome Treatment Market
14. South Korea Polycystic Ovarian Syndrome Treatment Market
15. Western Europe Polycystic Ovarian Syndrome Treatment Market
16. UK Polycystic Ovarian Syndrome Treatment Market
17. Germany Polycystic Ovarian Syndrome Treatment Market
18. France Polycystic Ovarian Syndrome Treatment Market
19. Italy Polycystic Ovarian Syndrome Treatment Market
20. Spain Polycystic Ovarian Syndrome Treatment Market
21. Eastern Europe Polycystic Ovarian Syndrome Treatment Market
22. Russia Polycystic Ovarian Syndrome Treatment Market
23. North America Polycystic Ovarian Syndrome Treatment Market
24. USA Polycystic Ovarian Syndrome Treatment Market
25. Canada Polycystic Ovarian Syndrome Treatment Market
26. South America Polycystic Ovarian Syndrome Treatment Market
27. Brazil Polycystic Ovarian Syndrome Treatment Market
28. Middle East Polycystic Ovarian Syndrome Treatment Market
29. Africa Polycystic Ovarian Syndrome Treatment Market
30. Polycystic Ovarian Syndrome Treatment Market Competitive Landscape and Company Profiles
31. Polycystic Ovarian Syndrome Treatment Market Other Major and Innovative Companies
35. Polycystic Ovarian Syndrome Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Polycystic Ovarian Syndrome Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on polycystic ovarian syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for polycystic ovarian syndrome treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The polycystic ovarian syndrome treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Type: Oral Contraceptives; Ornithine Decarboxylase Inhibitors; Insulin-Sensitizing Agents; Anti-Depressants; Diuretics; Aromatase Inhibitors2) By Surgery Type: Ovarian Wedge Resection; Laparoscopic Ovarian Drilling
3) By End User: Hospitals and Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Gynecology Centers, Feminist Health Centers
Subsegments:
1) By Oral Contraceptives: Combined Oral Contraceptives (COCs); Progestin-Only Pills2) By Ornithine Decarboxylase Inhibitors: Drugs Targeting Ovarian Androgen Production; Inhibitors Targeting Polyamine Synthesis
3) By Insulin-Sensitizing Agents: Metformin; Thiazolidinediones (TZDs)
4) By Anti-Depressants: Selective Serotonin Reuptake Inhibitors (SSRIs); Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
5) By Diuretics: Spironolactone; Furosemide
6) By Aromatase Inhibitors: Letrozole; Anastrozole
Key Companies Mentioned: Bristol-Myer Squibb Co; Bayer AG; Pfizer Inc.; Merck KGaA; Sanofi SA
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Polycystic Ovarian Syndrome Treatment market report include:- Bristol-Myer Squibb Co
- Bayer AG
- Pfizer Inc.
- Merck KGaA
- Sanofi SA
- AstraZeneca PLC
- Novartis AG
- Teva Pharmaceutical Industries Limited
- Abbott Laboratories
- Addex Therapeutics Ltd.
- BIOCAD
- Allergan plc.
- Johnson and Johnson
- Ferring Pharmaceuticals Inc.
- Takeda Pharmaceutical Company Limited
- Organon & Co
- Forendo Pharma Ltd.
- GlaxoSmithKline plc
- AbbVie Inc.
- Eli Lilly and Company
- Mylan NV
- Lupin Pharmaceuticals Inc.
- HRA Pharma SAS
- CooperSurgical Inc.
- TherapeuticsMD Inc.
- Agile Therapeutics Inc.
- OvaScience Inc.
- Aurobindo Pharma Limited
- Sun Pharmaceutical Industries Ltd.
- Zydus Cadila Healthcare Limited
- Glenmark Pharmaceuticals Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 5.03 Billion |
| Forecasted Market Value ( USD | $ 6.81 Billion |
| Compound Annual Growth Rate | 7.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 32 |
